Skip to main content
. 2017 Nov 3;7(11):e017387. doi: 10.1136/bmjopen-2017-017387

Table 8.

Effect-to-treatment analysis: sensitivity analysis

No Study mST CA=15% CA=19.3%
CEST METR CNTM p Value CEST METR CNTM p Value
1 Brandes153 9.95 (7.73–12.17) 9.64 1.20 (0.74–1.95) 90.98 (48.52 ─ 170.60) 0.979 9.44 1.23 (0.75–2.01) 5.30 (2.97 ─ 9.47) 0.585
2 Strik155 8.35 (7.67–9.03) 7.98 0.81 (0.44–1.48) −2.64 (−5.43 ─ −1.28) 0.302 8.35 0.95 (0.49–1.86) −11.73 (−24.39 ─ −5.64) 0.830
3 Abacioglu156 6.98 (6.23–7.73) 6.98 0.57 (0.37–0.89) −1.62 (−2.94 ─ −0.89) 0.016 6.73 0.55 (0.36–0.83) −2.04 (−3.43 ─ −1.22) 0.016
4 Berrocal157 5.60 (4.16–7.04) 5.35 0.19 (0.08–0.49) −1.00 (−2.77 ─ −0.36) <0.001 5.32 0.20 (0.08–0.51) −1.19 (−3.22 ─ −0.44) 0.001
5 WA (1–4) 7.27 (6.30–8.24) 7.07 0.59 (0.40–0.88) −1.68 (−2.93 ─ −0.96) 0.015 6.91 0.59 (0.40–0.88) −2.26 (−3.70 ─ −1.38) 0.027
6 WA (2–4)* 7.16 (6.25–8.08) 6.97 0.57 (0.39–0.85) −1.62 (−2.84 ─ −0.92) 0.011 6.82 0.57 (0.38–0.85) −2.14 (−3.52 ─ −1.30) 0.018
7 Sahinbas23 7.63 (6.52–8.74) 9.6 1.19 (0.59–2.40) 1.000 8.69 1.04 (0.77–1.41) 1.000

*Main comparator.

CA, coefficient of attenuation; CEST, cost-effective survival time; CNTM, cycles needed to treat per life month gained; METR, median effect-to-treatment ratio; mST, mean survival time; WA, weighted average.